Document ID: chunk:federal_register_of_legislation:F2025C00119:clause:3_1:p4
Version: federal_register_of_legislation:F2025C00119
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 4/69)
Character Range: 193081–202505

Bleomycin                                                                    Lymphoma
C6247                              Idarubicin                                                                   Acute myelogenous leukaemia (AML)
C6265                              Cladribine                                                                   Hairy cell leukaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Compliance with Authority Required procedures ‑ Streamlined Authority Code 6265
C6266               P6266          Fluorouracil                                                                 Patients requiring administration of fluorouracil by intravenous infusion
C6275                              Bleomycin                                                                    Germ cell neoplasms
                    P6276          Methotrexate                                                                 Patients receiving treatment with a high dose regimen
C6297               P6297          Fluorouracil                                                                 Patients requiring administration of fluorouracil by intravenous injection
C6383                              Aprepitant                                                                   Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures ‑ Streamlined Authority Code 6383
                                                                                                                The condition must be associated with cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                The treatment must be in combination with a 5‑hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle; AND
                                                                                                                Patient must be scheduled to be administered a chemotherapy regimen that includes either carboplatin or oxaliplatin.
                                                                                                                No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
                                                                                                                Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.
C6464                              Aprepitant                                                                   Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures ‑ Streamlined Authority Code 6464
                                                                                                                The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                The treatment must be in combination with a 5‑hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle; AND
                                                                                                                Patient must have had a prior episode of chemotherapy induced nausea or vomiting; AND
                                                                                                                Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; raltitrexed.
                                                                                                                No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
                                                                                                                Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.
C6562               P6562          Ipilimumab                                                                   Unresectable Stage III or Stage IV malignant melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures ‑ Streamlined Authority Code 6562
                                                                                                                Induction treatment
                                                                                                                The treatment must be the sole PBS‑subsidised therapy for this condition; AND
                                                                                                                Patient must not have received prior treatment with ipilimumab; AND
                                                                                                                The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.
                                                                                                                The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.
C6585               P6585          Ipilimumab                                                                   Unresectable Stage III or Stage IV malignant melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures ‑ Streamlined Authority Code 6585
                                                                                                                Re‑induction treatment